Tebentafusp (Kimmtrak®). HTA ID: 23064

Assessment Status Rapid Review Complete
HTA ID 23064
Drug Tebentafusp
Brand Kimmtrak®
Indication Tebentafusp is indicated as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Assessment Process
Rapid review commissioned 10/10/2023
Rapid review completed 13/11/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tebentafusp compared with the current standard of care.